<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In non-Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo> allogeneic stem cell transplantation (SCT) can be curative, but with standard dose conditioning patients may have substantial morbidity and mortality from <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft-versus-host disease</z:e> (GVHD); for aggressive <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e>, reduced intensity conditioning may result in higher recurrence </plain></SENT>
<SENT sid="1" pm="."><plain>Patients with advanced follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (n = 12), transformed B cell <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> (n = 11), and non-CD30+T cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> (n = 17) responsive to chemotherapy who had an HLA-identical sibling were offered T cell depleted (CAMPATH-1 G or H antibodies) SCT </plain></SENT>
<SENT sid="2" pm="."><plain>Conditioning was with ablative doses of chemotherapy or radiotherapy </plain></SENT>
<SENT sid="3" pm="."><plain>Before SCT, patients with follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> had a median of 3 treatment courses, and those with transformed B cell and those diagnosed with T cell non-Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo> had 2 (range, 1-3) </plain></SENT>
<SENT sid="4" pm="."><plain>At SCT the median age was 46 years (range, 21-59 years) and the number of CD34+ cells infused was 2.85 x 10(6)/kg </plain></SENT>
<SENT sid="5" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients showed engraftment but 7 patients (17.5%) developed GVHD </plain></SENT>
<SENT sid="6" pm="."><plain>In total 12 subjects expired of transplant-related causes (n = 6) or from disease recurrence </plain></SENT>
<SENT sid="7" pm="."><plain>One-year transplant-related mortality was 15% </plain></SENT>
<SENT sid="8" pm="."><plain>There was no difference in survival across diagnostic groups </plain></SENT>
<SENT sid="9" pm="."><plain>At a median of 1051 days, 70% survived and 68% are without disease </plain></SENT>
<SENT sid="10" pm="."><plain>By reducing the incidence and severity of GVHD, patients can tolerate myeloablative doses of chemotherapy satisfactorily </plain></SENT>
<SENT sid="11" pm="."><plain>This has resulted in low treatment-related mortality and adequate protection from disease recurrence </plain></SENT>
</text></document>